Table 3.
All Probands n = 176 |
|
---|---|
Genotype-positive subjects, n (%) | 66 (38) |
Sarcomere-positive subjects, n (%) | 62 (35) |
VUS only subjects, n (%) | 7 (4) |
At least one P/LP/VUS-LP variant, n (%) | |
MYBPC3 | 31 (18) |
|
21/10 (12/5.7) |
|
8 (4.6) |
MYH7 | 20 (11) |
TPM1 | 6 (3.4) |
TNNT2 | 2 (1) |
TNNI3 | 2 (1) |
MYL2 | 1 (0.6) |
MYL3 | 0 |
ACTC1 | 1 (0.6) |
TNNC1 | 2 (1) |
FLNC | 5 (2.8) |
|
1/6 (0.6) |
ALPK3 | 2/37 (5) |
TRIM63 | 1/50 (2) |
Multiple P/LP/VUS-LP variants, n (%) | 10 (5.7) |
|
4 (2.3) |
P—pathogenic; LP—likely pathogenic; VUS—variant of uncertain significance; MYBPC3—cardiac myosin-binding protein C; MYH7—myosin heavy chain; TPM1—tropomyosin; TNNT2—cardiac troponin T; TNNI3—cardiac troponin I; MYL2—regulatory myosin light chain; MYL3—essential myosin light chain; ACTC1—alpha-actin; TNNC1—troponin C; FLNC—filamin C; ALPK3—Alpha-protein kinase 3; TRIM63—tripartite motif containing 63.